Fox Foundation
 |
|
| Abbreviation | MJFF |
|---|---|
| Founded | 31 October 2000 |
| Founder | Michael J. Fox |
| 13-4141945 | |
| Legal status | 501(c)(3) Non-profit |
| Headquarters | New York City |
| Fields | Parkinson's disease clinical research |
| Robert W. Shakleton | |
| Todd Sherer | |
| Affiliations | MJFF Canada |
|
Revenue (2014)
|
$83,234,503 |
| Expenses (2014) | $83,537,775 |
|
Employees (2014)
|
109 |
|
Volunteers (2014)
|
17 |
| Mission | To ensure the development of better treatments, and ultimately a cure, for Parkinson's disease through an aggressively funded research agenda. |
| Website | www |
The Michael J. Fox Foundation for Parkinson's Research is dedicated to finding a cure for Parkinson's disease (PD) through an aggressively funded research agenda and to ensure the development of improved therapies for those living with Parkinson's today. Established by actor Michael J. Fox in 2000, the Foundation has since become the largest nonprofit funder of Parkinson's disease research in the world, investing more than $650 million in research to date. The Foundation's proactive approach to advancing Parkinson's disease science has made it "the most credible voice on Parkinson's research in the world". In 2010, the Foundation launched the first large scale clinical study on evolution biomarkers of the disease at a cost of $45 million over 5 years.
The Foundation targets people's high-risk, "translational" research—the work of translating basic scientific discoveries into simple treatments with definition to benefit the estimated five million people living with Parkinson's disease today.
The Foundation drives progress by awarding grants to ensure that the most promising research avenues are thoroughly funded, explored and carried forward toward pharmacy shelves. The Foundation's four annually recurring Pipeline Programs aim to speed research along the drug development pipeline. The Pipeline Programs include:
Rapid Response Innovation Awards quickly support high-risk, high-reward projects with little to no existing preliminary data, but potential to significantly impact our understanding or treatment of PD (an Edmond J. Safra Core Program for PD Research).
Target Validation Awards provide support for work demonstrating whether modulation of a novel biological target has impact in a PD-relevant pre-clinical model — an essential step to the development of potential targeted therapies (an Edmond J. Safra Core Program for PD Research).
Clinical Intervention Awards support clinical testing of promising PD therapies that may significantly and fundamentally improve treatment of PD (an Edmond J. Safra Core Program for PD Research).
Therapeutics Development Initiative, an industry-exclusive support program for preclinical development of Parkinson’s disease therapies with potential to fundamentally alter disease course and/or improve treatment of symptoms above and beyond current standards of care.
The Pipeline Programs are complemented by the Foundation's Critical Challenges in Parkinson's Disease program, which provides funds for top research priorities.Critical Challenges in 2009/2010 include: speeding research on PD genetic targets, LRRK2 and alpha-synuclein; advancing research on neurotrophic factors; identifying biomarkers of PD; understanding patient's unmet needs, like postural instability and gait disturbances; and, promoting collaborations with the Arizona Parkinson's Disease Consortium.
...
Wikipedia